Literature DB >> 27886373

Clemizole hydrochloride blocks cardiac potassium currents stably expressed in HEK 293 cells.

Ling-Jun Jie1, Wei-Yin Wu1, Gang Li1, Guo-Sheng Xiao1, Shetuan Zhang2, Gui-Rong Li1, Yan Wang1.   

Abstract

BACKGROUND AND
PURPOSE: Clemizole, a histamine H1 receptor antagonist has a potential therapeutic effect on hepatitis C infection and also potently inhibits TRPC5 ion channels. The aim of the present study was to investigate whether clemizole blocks cardiac K+ currents and thus affects cardiac repolarization. EXPERIMENTAL APPROACH: Whole-cell patch techniques was used to examine the effects of clemizole on hERG channel current, IKs and Kv 1.5 channel current in HEK 293 cell expression systems as well as on ventricular action potentials of guinea pig hearts. Isolated hearts from guinea pigs were used to determine the effect on the ECG. KEY
RESULTS: Clemizole decreased hERG current by blocking both open and closed states of the channel in a concentration-dependent manner (IC50 : 0.07 μM). The S631A, S636A, Y652A and F656V hERG mutant channels reduced the inhibitory effect of clemizole (IC50 : 0.82, 0.89, 1.49 and 2.98 μM, respectively), suggesting that clemizole is a pore blocker of hERG channels. Clemizole also moderately decreased IKs and human Kv 1.5 channel current. Moreover, clemizole increased the duration of the ventricular action potential in guinea pig hearts and the QTc interval in isolated perfused hearts from guinea pigs, in a concentration-dependent manner (0.1-1.0 μM). CONCLUSION AND IMPLICATIONS: Our results provide the first evidence that clemizole potently blocks hERG channels, moderately inhibits cardiac IKs , delays cardiac repolarization and thereby prolongs QT interval. Thus, caution should be taken when clemizole is used as a TRPC5 channel blocker or for treating hepatitis C infection.
© 2016 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27886373      PMCID: PMC5241390          DOI: 10.1111/bph.13679

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  57 in total

1.  Local anesthetic activity of some antihistamines and its relationship with the antihistaminic and anticholinergic activities.

Authors:  P NARANJO; E B DE NARANJO
Journal:  Arch Int Pharmacodyn Ther       Date:  1958-01-01

2.  Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction.

Authors:  Toshihiko Nishimura; Toshiko Nishimura; Yajing Hu; Manhong Wu; Edward Pham; Hiroshi Suemizu; Menashe Elazar; Michael Liu; Ramazan Idilman; Cihan Yurdaydin; Peter Angus; Catherine Stedman; Brian Murphy; Jeffrey Glenn; Masato Nakamura; Tatsuji Nomura; Yuan Chen; Ming Zheng; William L Fitch; Gary Peltz
Journal:  J Pharmacol Exp Ther       Date:  2012-11-08       Impact factor: 4.030

3.  The calmodulin inhibitor N-(6-aminohexyl)-5-chloro-1-naphthalene sulphonamide directly blocks human ether à-go-go-related gene potassium channels stably expressed in human embryonic kidney 293 cells.

Authors:  Xiao-Hua Zhang; Man-Wen Jin; Hai-Ying Sun; Shetuan Zhang; Gui-Rong Li
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

4.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.

Authors:  James T Milnes; Olivia Crociani; Annarosa Arcangeli; Jules C Hancox; Harry J Witchel
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

Review 5.  Non-selective cation channel blockers: potential use in nervous system basic research and therapeutics.

Authors:  Fernando Peña; Benito Ordaz
Journal:  Mini Rev Med Chem       Date:  2008-07       Impact factor: 3.862

6.  Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound.

Authors:  Shigeki Kiyonaka; Kenta Kato; Motohiro Nishida; Kazuhiro Mio; Takuro Numaga; Yuichi Sawaguchi; Takashi Yoshida; Minoru Wakamori; Emiko Mori; Tomohiro Numata; Masakazu Ishii; Hiroki Takemoto; Akio Ojida; Kenta Watanabe; Aya Uemura; Hitoshi Kurose; Takashi Morii; Tsutomu Kobayashi; Yoji Sato; Chikara Sato; Itaru Hamachi; Yasuo Mori
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

7.  Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel.

Authors:  Zhi Su; Ruth Martin; Bryan F Cox; Gary Gintant
Journal:  J Mol Cell Cardiol       Date:  2004-01       Impact factor: 5.000

Review 8.  hERG potassium channels and cardiac arrhythmia.

Authors:  Michael C Sanguinetti; Martin Tristani-Firouzi
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

9.  Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis.

Authors:  Shirit Einav; Doron Gerber; Paul D Bryson; Ella H Sklan; Menashe Elazar; Sebastian J Maerkl; Jeffrey S Glenn; Stephen R Quake
Journal:  Nat Biotechnol       Date:  2008-09       Impact factor: 54.908

Review 10.  Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.

Authors:  Akshay Gupta; Andrew T Lawrence; Kousik Krishnan; Clifford J Kavinsky; Richard G Trohman
Journal:  Am Heart J       Date:  2007-06       Impact factor: 4.749

View more
  7 in total

1.  Clemizole hydrochloride blocks cardiac potassium currents stably expressed in HEK 293 cells.

Authors:  Ling-Jun Jie; Wei-Yin Wu; Gang Li; Guo-Sheng Xiao; Shetuan Zhang; Gui-Rong Li; Yan Wang
Journal:  Br J Pharmacol       Date:  2017-01-12       Impact factor: 8.739

2.  Anti-Ro52 antibody acts on the S5-pore linker of hERG to chronically reduce channel expression.

Authors:  John Szendrey; Shawn M Lamothe; Stephanie Vanner; Jun Guo; Tonghua Yang; Wentao Li; Jordan Davis; Mala Joneja; Adrian Baranchuk; Shetuan Zhang
Journal:  Cardiovasc Res       Date:  2019-08-01       Impact factor: 10.787

3.  Noradrenaline up-regulates volume-regulated chloride current by PKA-independent cAMP/exchange protein activated by cAMP pathway in human atrial myocytes.

Authors:  Guo-Sheng Xiao; Yan-Hui Zhang; Yan Wang; Hai-Ying Sun; Clive M Baumgarten; Gui-Rong Li
Journal:  Br J Pharmacol       Date:  2018-07-08       Impact factor: 8.739

4.  Involvement of TRPC4 and 5 Channels in Persistent Firing in Hippocampal CA1 Pyramidal Cells.

Authors:  Alberto Arboit; Antonio Reboreda; Motoharu Yoshida
Journal:  Cells       Date:  2020-02-05       Impact factor: 6.600

5.  Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.

Authors:  Zheng Zequn; W U Yujia; Q I A N Dingding; L I A N Jiangfang
Journal:  Eur J Pharmacol       Date:  2020-12-17       Impact factor: 4.432

6.  An in Vitro Assay of hERG K + Channel Potency for a New EGFR Inhibitor FHND004.

Authors:  Tao Jin; Bingxue Hu; Shanshan Chen; Qiang Wang; Xue Dong; Yin Zhang; Yongqiang Zhu; Zhao Zhang
Journal:  Front Pharmacol       Date:  2018-05-31       Impact factor: 5.810

Review 7.  Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5.

Authors:  Zefeng Zhao; Songsong Ruan; Xiaoming Ma; Qian Feng; Zhuosong Xie; Zhuang Nie; Peinan Fan; Mingcheng Qian; Xirui He; Shaoping Wu; Yongmin Zhang; Xiaohui Zheng
Journal:  Biomolecules       Date:  2019-12-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.